The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The Federal Trade Commission (FTC) continues slicing a machete through the patent thicket. On Tuesday, the agency sent warning letters to 10 pharmaceutical companies threatening legal action for ...
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs. This week, the Federal Trade Commission ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...
The FTC is investigating improper patent listings, including Novo Nordisk's Ozempic, which could impact shareholders. Novo Nordisk's GLP-1 agonists, including Ozempic, have become a significant ...